Drug Trial Radar · NCT05996432
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
May 17, 2023
Primary completion
Nov 30, 2026
Study completion May 31, 2029
Sponsor
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Conditions
- Head and Neck Squamous Cell Carcinoma
- Brain Metastases
Interventions
Magnetic Resonance Imaging (MRI)Procedure
Participants will undergo Magnetic Resonance Imaging
Positron Emission Tomography (PET)Procedure
Participants will undergo Positron Emission Tomography
18F-fluoromisonidazoleDrug
Given by IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Validate non-invasive, MRI-based markers of tumor hypoxia in patients with brain metastases or head and neck cancer with and without evidence of tumor hypoxia identified by 18F-FMISO-PET-CTTime frame: 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.